Tag: Hepatitis b

Chronic hepatitis B affects over 250 million people worldwide. Choosing what is the best medication for hepatitis B depends on various factors, including the patient's liver health, viral load, and individual response to treatment.

Globally, 77% of people living with HIV were accessing antiretroviral therapy (ART) in 2024 [1.11.1, 1.11.2]. For those on Biktarvy, a key question is: what happens if you stop Biktarvy? Discontinuation without medical guidance poses significant health risks [1.2.1, 1.3.2].

According to the U.S. Food and Drug Administration (FDA) prescribing information, Kesimpta is contraindicated in patients with an active Hepatitis B virus (HBV) infection or a history of a life-threatening injection-related or hypersensitivity reaction to the drug. Understanding **what are the contraindications for Kesimpta** is crucial for patient safety and effective treatment planning.

Before starting Ocrevus (ocrelizumab), a medication for multiple sclerosis, it is crucial for a healthcare provider to conduct a thorough medical evaluation to identify any safety concerns or pre-existing conditions. Understanding what are the contraindications for Ocrevus infusion is a vital step to ensure patient safety and prevent serious adverse events.

In clinical trials, the most common adverse reactions reported in adults taking lamivudine for HIV treatment included headache, nausea, malaise, and fatigue. Understanding what are the adverse reactions of lamivudine is crucial for both patients and healthcare providers to manage expectations and promptly recognize potential complications.

While the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine has a significantly lower risk of causing peripheral neuropathy compared to older agents like stavudine, it can still occur as a side effect. This condition can manifest as numbness, tingling, or burning sensations, primarily in the hands and feet.

Tenofovir is a cornerstone antiviral medication, with a history spanning back to its patent in 1996 and FDA approval in 2001. Knowing **what pharmaceutical class is tenofovir** is crucial for understanding how it combats viruses like HIV and hepatitis B. It is categorized as a nucleotide reverse transcriptase inhibitor (NtRTI), a key type of antiretroviral drug.

While tenofovir is a highly effective antiviral drug, its different formulations have distinct safety profiles. A key question for patients and clinicians is which of the following side effects is common with tenofovir, particularly when comparing the older tenofovir disoproxil fumarate (TDF) and the newer tenofovir alafenamide (TAF). The answer depends heavily on the specific formulation and individual patient factors.

Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI) that is a mainstay of many antiretroviral therapy combinations. People who take tenofovir do so for several crucial reasons, most commonly for the treatment of Human Immunodeficiency Virus (HIV) infection, the management of chronic Hepatitis B (HBV) infection, or for HIV prevention, known as pre-exposure prophylaxis (PrEP).

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that has been a cornerstone of HIV treatment and prevention for over two decades. Knowing what does emtricitabine target is key to understanding its efficacy in slowing the progression of Human Immunodeficiency Virus (HIV) and managing Hepatitis B Virus (HBV). By inhibiting a specific viral enzyme, the medication effectively prevents the virus from replicating and overwhelming the immune system.